Abstract The study was designed to evaluate efficacy and superiority of capecitabine/bevacizumab ? vinorelbine (CAP/BEV/VIN) compared to CAP/BEV alone. Main purpose was to introduce a taxane-/anthracycline-free firstline treatment in advanced breast cancer (ABC), in order to avoid long-term toxicities. In this open-label, superiority, phase 3 trial, patients with HER2-negative ABC were randomized 1:1 to receive either oral CAP at 1000 mg/m The 1-and 2-year OS rates appeared to be similar (78.0 and 77.0 %; 53.0 and 54.0 %). Toxicity profiles were generally mild and manageable. Adverse events occurred more frequently in arm B. Regarding the balance between clinical efficacy (PFS, OS) and toxicity, the CAP/BEV combination provides a favourable treatment option in first-line ABC avoiding taxane-and/or anthracycline-induced longterm toxicity. Superiority of CAP/BEV/VIN was not met, and side effects were even enhanced. Nevertheless, no safety issues occurred.
Introduction
Despite many new treatment options, advanced breast cancer (ABC) remains essentially incurable. Taxanes, especially paclitaxel (PAC), and anthracyclines represent standard agents in first-line chemotherapy [1, 2] . Unfortunately, taxanes and anthracyclines are associated with substantial side effects, including peripheral neuropathy, myelosuppression, cardiotoxicity, and hair loss [3, 4] that heavily impair patients' performance and quality of life [5, 6] . Prolonged taxane and anthracycline exposure is not feasible because of cumulative toxic effects [7] . Therefore, capecitabine (CAP)-based combinations provide an effective and less toxic alternative for patients without rapidly progressive disease [8] .
The addition of bevacizumab (BEV) to first-line chemotherapy in the E2100, AVADO, and RIBBON-1 trials resulted in prolongation of progression-free survival (PFS) and improved overall response rates (ORR) as compared to chemotherapy alone [9] [10] [11] . The placebocontrolled RIBBON-1 trial [11] was the first study demonstrating significantly improved ORR and PFS by adding BEV to first-line chemotherapy with either taxane-/ anthracycline or CAP -based treatment. The TURANDOT trial [12, 13] , a randomised phase 3 non-inferiority headto-head study, assessed efficacy of BEV in combination with either PAC or CAP in first-line treatment for HER2-negative ABC.
Recently presented final OS data indicated non-inferiority of CAP/BEV (demonstrated in the stratified per-protocol analysis, supported by the stratified intent-to-treat analysis but not in the unstratified analysis). The OS curves seemed much the same, both in the per-protocol or the intent-to-treat analysis [13] . Although both, the TUR-ANDOT and RIBBON-1 trial, demonstrated improved PFS for taxanes in combination with BEV, this did not translate into survival benefit.
Vinorelbine (VIN) monotherapy, evaluated in several clinical trials after failure of taxane-/anthracycline-based first-line metastatic treatment, yielded ORRs of about 29 % [14, 15] . VIN in combination with CAP revealed promising clinical activity and good tolerability in the neoadjuvant as well as in the metastatic setting [16] [17] [18] . Overlapping toxicities of both substances were rare.
CARIN was developed to improve efficacy through combination of VIN with CAP/BEV, thus offering an effective taxane-/anthracycline-free treatment option in first-line therapy of ABC. Primary objective was to demonstrate clinical superiority of CAP/BEV/VIN compared to CAP/BEV in terms of PFS. Secondary objectives included ORR, safety, and OS.
Methods Patients
Eligible patients had HER2/-negative measurable or nonmeasurable disease, inoperable locally recurrent or ABC, no previous chemotherapy for advanced disease, and ECOG performance status B2; were aged C18 years; and had no sign of brain metastases. Adjuvant chemotherapy with either CAP or BEV or VIN was allowed if completed at least 12 months before randomisation. Further inclusion criteria comprised adequate liver, renal, cardiac, and haematological function; no uncontrolled hypertension; or proteinuria. All patients provided written informed consent. Independent ethics committees at all participating sites approved the protocol and all modifications.
Study design
CARIN was an open-label, randomised phase 3 trial. 600 patients were randomly assigned (1:1) to receive either CAP/BEV (arm A) or CAP/BEV/VIN (arm B). Randomisation was stratified by prior (neo)adjuvant therapy with taxanes or anthracyclines (yes/no) and hormone receptor status (±).
In both arms, CAP was administered orally at 1000 mg/ m 2 (twice daily, days 1-14, q3w), combined with intravenous BEV at 15 mg/kg (day 1, q3w). In arm B, intravenous VIN was added to CAP/BEV at 25 mg/m 2 (days 1 ? 8, q3w). Treatment was continued until progression of disease (PD), unacceptable toxicity, or withdrawal of consent. If any drug was discontinued for reasons of toxicity, treatment continued on the reduced regimen at allocated dosages. No BEV dose reduction was permitted, but treatment could be delayed. Beyond progression, all patients were offered standard-of-care treatment.
Efficacy and safety assessments
Tumour assessments according to RECIST 1.0 were performed at baseline, thereafter every 9 weeks until PD. After PD, patients were followed up for survival every 3 months over up to 3 years after last patient in.
Safety and tolerability assessments in terms of routine laboratory parameters, urinalysis, and vital signs were performed on a regular basis every cycle. Adverse events (AEs) were reported systematically throughout the study, including a 30-day safety follow-up period after treatment discontinuation. Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria, v3.0 and classified according to MedDRA v17.0 coding.
Statistical analysis
PFS as the primary objective was calculated from the date of randomisation to the date of first signs of tumour progression or death from any cause. Patients not experiencing PD or death were censored at the date of either last visit or start of new antineoplastic treatment. Calculating a dropout rate of 10 %, a total of 600 patients (a = 0.05, twosided, power = 80 %) were to be enrolled. At study data cut-off for analysis, less events than expected were observed, reducing the power to detect the initially calculated PFS difference between treatment arms (8.0 vs. 10.3; HR = 0.78) to 75 %. Secondary endpoints included ORR, OS, and safety.
Treatment effects on PFS were calculated and compared between treatment arms and within subgroups using the Kaplan-Meier and Cox regression method. Hazard ratios (HR) and 95 % confidence intervals (CI) were estimated by Cox proportional hazards analysis. Subgroup analyses were considered exploratory, no alpha adjustment for multiple testing was applied to the eight comparisons of subgroups: 'age (\65 vs. C65 years)', 'number of metastatic sites (\3 vs. C3 sites)', 'prior taxane/anthracycline (yes/no)', 'visceral disease (involved/not involved)', 'triple negative breast cancer (TNBC yes/no)', 'ECOG performance status (0 vs. 1/2)', 'prior palliative endocrine therapy (yes/no)', and 'bone metastases (yes/no)'.
Since the OS curves for treatment comparison appeared non-proportional, average hazard ratios were determined by weighted Cox regression method [19] . For OS subgroup analyses, the Cox proportional hazards were estimated.
For objective response evaluation, treatment groups were compared using Cochran Mantel-Haenszel test. Patients were considered evaluable for response if they had measurable disease at baseline.
Demographic and clinical characteristics were evaluated descriptively. All statistical analyses were performed using Statistica v10.0 and R v3.2.0. Patient demographic and clinical baseline characteristics were generally well balanced between both arms (Table 1) . Notably, the full analysis population was characterized by a considerable portion of patients older than 65 years (arm A 
Results

Patients
:
Treatment exposure
Median duration of treatment was comparable between both arms (arm A: 27.9 weeks; arm B: 29.0 weeks). Median dose intensities for CAP were 84 and 79 % and for BEV 98 and 94 % in arms A and B, respectively. VIN dose intensity was 85 % (data not shown).
Efficacy
The addition of VIN slightly increased median PFS compared to CAP/BEV alone (8.8 vs. 9.6 months; HR 0.84 [95 % CI 0.70-1.01], log-rank P = 0.058), and therefore, the criteria for superiority of CAP/BEV/VIN were not met ( (Fig. 4, Serious AEs, deemed to be treatment-related by the investigator, led to death of three patients in arm A (pancytopenia, thromboembolic event, pulmonary embolism), and of two patients in arm B (pulmonary embolism and leukopenia associated with sepsis) (data not shown).
Discussion
The CARIN trial, a German phase 3 study, aimed to improve efficacy of CAP/BEV by adding VIN to establish a less toxic alternative to taxane-/anthracycline-based firstline treatment. PFS was the primary endpoint assuming a Compared to other phase 3 studies, the CARIN median PFS for CAP/BEV (8.8 months) was in the range of that observed in the CAP/BEV cohort of the TURANDOT (8.1 months) [12, 13] and the RIBBON-1 (9.2 months) [11] trials. RIBBON-1 [11] was the first study investigating efficacy and safety of BEV versus placebo combined with different standard chemotherapy backbones to be chosen by investigators before random assignment. This led to a pronounced imbalance between the treatment arms regarding taxane pre-treatment, with 40 % in the CAP/ BEV arm and only 15 % in the taxane/anthracycline arm, thus hampering comparability of results. ORR and median PFS were higher in each BEV combination. This effect was most obvious in the CAP/BEV arm. The TURANDOT [12, 13] trial investigated in a randomised fashion whether OS with CAP plus BEV would be non-inferior to PAC plus BEV. Although response rates and PFS were significantly higher for PAC-BEV, results of the final analysis did not point to a survival benefit [13] . The debate regarding the use of taxanes and/or anthracyclines in first-line treatment of ABC on OS is still ongoing. The CARIN trial confirmed the efficacy of the taxane-/anthracycline-free CAP/BEV combination with a median OS of 25.1 months, which is quite comparable to 26.1 months reported from the CAP/BEV arm in the TURANDOT trial. Differences in OS between CARIN and TURANDOT may be explained by a significant discrepancy regarding pre-treatment with adjuvant or neoadjuvant taxanes in TURANDOT and CARIN (20 and 34 %, respectively), pointing to a more favourable prognosis for TURANDOT patients, when compared to the patient population in the CARIN trial. Notably, the 1-year OS rate in the CAP/BEV treatment arms was fairly comparable between CARIN (78 %), TURANDOT (81 %), and RIB-BON-1 (81 %) trials, respectively. The taxane-containing PAC-BEV treatment in TURANDOT not only revealed OS of 30.2 months but also enhanced peripheral neuropathy. OS for CAP/BEV/VIN was 27.2 months.
On closer inspection, the CARIN OS estimates showed divergent curve characteristics beyond 33 months. This divergence may represent delayed clinical efficacy of arm B. The divergence may also be due to the differently responding subgroups. Particularly, subgroups with taxane/ anthracycline pre-treatment and without visceral involvement obtained clinically meaningful survival benefits in the CAP/BEV/VIN approach, confirming VIN's therapeutic activity. Nonetheless, these subgroup findings require further examination in larger patient cohorts.
Regarding response induction, taxane/anthracyclinebased combinations with BEV seem to be more effective than CAP/BEV [8, 9] . Patients presenting with lifethreatening metastatic organ involvement may thus benefit from taxane-/anthracycline-based first-line treatment. However, since almost all patients are at risk of developing taxane-induced neurotoxicity [21] that impairs patients' daily life performance and overall quality of life, taxane treatment should be reserved for more advanced stages.
Undoubtedly, vinca alkaloids can also induce characteristic peripheral neurotoxicity [22, 23] . In this aspect, VIN added toxicity to the CAP/BEV combination. Treatment discontinuations due to toxicities occurred more frequently within CAP/BEV/VIN as compared to CAP/BEV alone, suggesting that VIN toxicities are in some way more severe or protracted. However, in the CARIN VIN-containing arm, only 10 of 295 patients developed grade 3 and 1 patient grade 4 polyneuropathy. In general, AEs [ -grade 3 were rarely seen. Common side-effects of VIN and main dose limiting toxicities were neutropenia, as observed in other studies [15, 24, 25] . VIN did not cause profound thrombocytopenia. Other toxicities were mild to moderate and generally well manageable. There was an also manageable increase in adverse events due to hand-foot syndrome. The incidence (all grades) was higher in the CAP/BEV arm than in the CAP/ BEV/VIN arm in spite of comparable dose intensities in both arms. In CARIN, hand-foot syndrome was mostly responsible for discontinuations of CAP. However, as compared to the BEV-PAC treatment arm in TURANDOT, the proportion of treatment discontinuations due to toxic effects in our CAP/BEV/VIN arm was somewhat lower (34 and 38 %, respectively).
The safety profile of BEV was consistent with known side effects [26, 27] and did not lead to a significant increase in toxicity. Severe side effects were rare even in patients with long-term treatment. 
Conclusion
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